Previous studies in advanced NSCLC and renal cell carcinoma (RCC) have shown that in patients treated with anti-PD-1/PD-L1 antibodies, OR is associated with higher OS rates [22, 23]. This evidence concerns the gene CD274 and renal cell carcinoma.